2025 年至 2032 年偏头痛治疗市场（依治疗剂、给药途径及地区划分）

偏头痛药物市场规模预计在 2025 年为 68.509 亿美元，预计到 2032 年将达到 129.314 亿美元，2025 年至 2032 年的年复合成长率（CAGR）为 9.5%。

偏头痛是一种神经系统疾病，其特征是头部某一区域出现剧烈的搏动性或搏动性疼痛。疼痛通常为单侧搏动性疼痛，且活动时疼痛加剧。偏头痛是一种容易引起其他征兆和症状的头痛，例如噁心和视力模糊。虽然偏头痛无法治愈，但药物可以帮助预防、停止或防止症状和征兆恶化。

市场动态

偏头痛盛行率的上升、对安全有效治疗的需求不断增长、人们对偏头痛及其治疗方法的认识不断提高以及全球研发的不断活性化，预计将在预测期内推动全球偏头痛药物市场的成长。例如，偏头痛是一种严重且常见的神经系统疾病，严重影响生活品质。 2020年，偏头痛被世界卫生组织列为导致残障年限损失最多的神经系统疾病。

2022年2月，Biohaven製药控股有限公司和辉瑞公司报告称，欧洲药品管理局（EMA）人用药品委员会对Rimegepant给予了正面评价。 Rimegepant 75毫克（口溶片）被建议上市许可，用于成人有或无征兆偏头痛的急性治疗，以及每月发作四次或以上偏头痛的成人核准性偏头痛的征兆治疗。

本次调查的主要特点

• 本报告对全球偏头痛药物市场进行了详细分析，并以 2024 年为基准年，提供了预测期 2025-2032 的市场规模（百万美元）和年复合成长率(CAGR)。
• 它还强调了各个领域的潜在商机，并说明了该市场的有吸引力的投资提案矩阵。
• 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的主要考察。
• 该报告根据公司亮点、产品系列、关键亮点、绩效和策略等参数，概述了全球偏头痛治疗药物市场的主要企业。
• 本报告的见解将使负责人和企业经营团队能够就未来的产品发布、新兴车型、市场扩张和行销策略做出明智的决策。
• 全球偏头痛治疗药物市场报告涉及该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
• 相关人员可以透过用于分析全球偏头痛药物市场的各种策略矩阵来更轻鬆地做出决策。

目录

第一章：调查目标和先决条件

• 调查目的
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第三章：市场动态、法规与趋势分析

• 市场动态
  • 全球偏头痛盛行率不断上升
  • 药物副作用和未确诊病例的增加
  • 安全有效治疗的需求不断增加
• 影响分析
• 主要亮点
• 监管情景
• 产品发布/核准
• PEST分析
• 波特分析
• 併购场景

4. 全球偏头痛治疗市场（依治疗类别），2020 年至 2032 年

• 止痛药
• 预防性药物

5. 2020 年至 2032 年按给药途径分類的全球偏头痛药物市场

• 口腔和鼻腔
• 注射

6. 2020 年至 2032 年全球偏头痛药物市场（按地区）

• 北美洲
• 美国
• 加拿大
• 欧洲
• 德国
• 英国
• 西班牙
• 法国
• 义大利
• 俄罗斯
• 其他欧洲国家
• 亚太地区
• 中国
• 印度
• 日本
• 澳洲
• 韩国
• ASEAN
• 其他亚太地区
• 拉丁美洲
• 巴西
• 阿根廷
• 墨西哥
• 其他拉丁美洲
• 中东
• 海湾合作委员会国家
• 以色列
• 其他中东地区
• 非洲
• 南非
• 北非
• 中部非洲

第七章 竞争态势

• Pfizer Inc.
• Novartis International AG
• Merck & Co. Inc.
• GlaxoSmithKline PLC
• Eli Lilly and Company
• AstraZeneca PLC
• Amgen Inc.
• Allergan Inc.
• Bausch Health Companies Inc.
• Teva Pharmaceutical Industries Ltd.

第 8 章 章节

• 调查方法
• 关于出版商

Migraine Therapeutic Market is estimated to be valued at USD 6,850.9 Mn in 2025 and is expected to reach USD 12,931.4 Mn by 2032, growing at a compound annual growth rate (CAGR) of 9.5% from 2025 to 2032.

Migraine is a neurological disorder often described as intense pulsing or throbbing pain in one area of the head. The pain is often unilateral and pulsating in nature, which can often be worsened by physical activity. Migraines are a type of headache that tend to cause other signs and symptoms, too, such as nausea and vision problems. There's no cure for migraines yet, but medicines can help prevent or stop them, or keep signs and symptoms from getting worse.

Market Dynamics

Increase in prevalence of migraine, increase in demand for safe and effective treatment, increase in awareness about migraine and its treatment options, and rise in research and development across the world are major factors expected to propel the growth of the global migraine therapeutic market during the forecast period. For instance, migraine is a serious and common neurological condition with a serious impact on quality of life. In 2020, migraine has been ranked by WHO as the most prevalent neurological condition causing the highest loss of years due to disability.

In February 2022, Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc. reported that the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) adopted a positive opinion for Rimegepant. It is recommended as the 75 mg dose of Rimegepant (available as an orally dissolving tablet) for marketing authorization for both the acute treatment of migraine with or without aura in adults and the preventive treatment of episodic migraine in adults who have at least four migraine attacks per month.

Key features of the study

• This report provides in-depth analysis of the global migraine therapeutic market, and provides market size (USD Mn) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global migraine therapeutic market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Pfizer Inc., Novartis International AG, Merck & Co. Inc., GlaxoSmithKline PLC, Eli Lilly and Company, AstraZeneca PLC, Amgen Inc., Allergan Inc., Bausch Health Companies Inc., and Teva Pharmaceutical Industries Ltd., among others.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global migraine therapeutic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global migraine therapeutic market.

Market Segmentation

• Global Migraine Therapeutic Market, By Therapeutics
  • Pain-relieving Medications
  • Preventive Medications
• Global Migraine Therapeutic Market, By Route of Administration
  • Oral and Nasal
  • Injection
• Global Migraine Therapeutic Market, By Geography
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Company Profiles
  • Pfizer Inc.
  • Novartis International AG
  • Merck & Co. Inc.
  • GlaxoSmithKline PLC
  • Eli Lilly and Company
  • AstraZeneca PLC
  • Amgen Inc.
  • Allergan Inc.
  • Bausch Health Companies Inc.
  • Teva Pharmaceutical Industries Ltd.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Therapeutics
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Geography
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Increase in prevalence of migraine around the world
  • Adverse effects of drugs and increasing undiagnosed cases
  • Increase in demand for safe and effective treatment
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Migraine Therapeutic Market, By Therapeutics, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Pain-relieving Medications
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Preventive Medications
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

5. Global Migraine Therapeutic Market, By Route of Administration, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral and Nasal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Injection
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

6. Global Migraine Therapeutic Market, By Geography, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
  • Country
• U.S.
• Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
  • Country
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
  • Country
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
  • Country
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
  • Country
• GCC Countries
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
  • Country
• South Africa
• North Africa
• Central Africa

7. Competitive Landscape

• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis International AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck & Co. Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GlaxoSmithKline PLC
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Eli Lilly and Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AstraZeneca PLC
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Amgen Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Allergan Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bausch Health Companies Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Teva Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Analyst Views

8. Section

• Research Methodology
• About us